UBS Group
HAE icon

UBS Group’s Haemonetics HAE Stock Holding History

UBS Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-77,500
Closed -$3.78M – 10786
2025
Q3 		$3.78M Buy
+77,500
New +$4.8M ﹤0.01% 4330

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group's HAE Position: Q1 2026 in Review

UBS Group reduced its Haemonetics (HAE) stake by 2.4% in Q1 2026, selling an estimated $851K and leaving 526,617 shares worth $29.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2186.

UBS Group first reported a position in HAE in Q4 2014 and has held it in 46 quarters since. The position peaked at $70.8M in Q3 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • UBS Group held 526,617 shares of Haemonetics worth $29.7M as of Q1 2026.
  • UBS Group sold 13,060 Haemonetics shares in Q1 2026, an estimated $851K.
  • Haemonetics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2186 holding.
  • UBS Group first reported a position in Haemonetics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Haemonetics position peaked at $70.8M in Q3 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.